Adam J Olszewski

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Re...

Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic...